Tuberculosis Research Today is a free monthly online journal that collates and summarizes the latest research about Tuberculosis, including details on symptoms, causes, treatment, pulmonary, mycobacterium.

Volume 5 (2008), Issue 6 (June)

1. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
   Am J Respir Crit Care Med, 177(12): 1391-6. [Abstract] [Full-text]
2. Challenges in estimating the total burden of drug-resistant tuberculosis.
   Am J Respir Crit Care Med, 177(12): 1302-6. [Abstract] [Full-text]
3. Advanced survey of tuberculosis transmission in a complex socioepidemiologic scenario with a high proportion of cases in immigrants.
   Clin Infect Dis, 47(1): 8-14. [Abstract] [Full-text]
4. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.
   Curr Opin Rheumatol, 20(4): 443-9. [Abstract] [Full-text]
5. Natural killer cell subpopulations in putative resistant individuals and patients with active Mycobacterium tuberculosis infection.
   Scand J Immunol, 68(1): 92-102. [Abstract] [Full-text]
6. Diabetic control and risk of tuberculosis: a cohort study.
   Am J Epidemiol, 167(12): 1486-94. [Abstract] [Full-text]
7. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment.
   Clin Infect Dis, 46(12): 1844-51. [Abstract] [Full-text]
8. Tuberculosis of thymus--a case report.
   Heart Lung Circ, 17(4): 345-6. [Abstract] [Full-text]
9. CD4+ CD25+ Treg cells inhibit human memory gammadelta T cells to produce IFN-gamma in response to M tuberculosis antigen ESAT-6.
   Blood, 111(12): 5629-36. [Abstract] [Full-text]
10. The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population.
    J Infect Dis, 198(1): 90-4. [Abstract] [Full-text]
11. Systems biology of persistent infection: tuberculosis as a case study.
    Nat Rev Microbiol, 6(7): 520-8. [Abstract] [Full-text]
12. CT differentiation of anthracofibrosis from endobronchial tuberculosis.
    AJR Am J Roentgenol, 191(1): 247-51. [Abstract] [Full-text]
13. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis.
    J Control Release, 129(2): 100-6. [Abstract] [Full-text]
14. Effect of multiple genetic polymorphisms on antigen presentation and susceptibility to Mycobacterium tuberculosis infection.
    Infect Immun, 76(7): 3221-32. [Abstract] [Full-text]
15. Reduced erythrocyte CR1 levels in patients with pulmonary tuberculosis is an acquired phenomenon.
    Clin Immunol, 128(1): 109-15. [Abstract] [Full-text]
16. A survey of tuberculosis services in the UK.
    Arch Dis Child, 93(7): 575-7. [Abstract] [Full-text]
17. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules.
    Clin Exp Immunol, 153(1): 56-62. [Abstract] [Full-text]
18. Extensively drug-resistant tuberculosis: current challenges and threats.
    FEMS Immunol Med Microbiol, 53(2): 145-50. [Abstract] [Full-text]
19. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
    Thorax, 63(7): 627-34. [Abstract] [Full-text]

© 2004-2008 Tuberculosis Research Today. All Rights Reserved.